Menopause care is one of the most active corners of digital health right now. Midi Health, Alloy, Elektra Health, Stella, Winona, and a long tail of new VC-backed entrants are racing to serve a patient population that most of healthcare has spent decades ignoring.

We've had a front-row seat to this rise at our company Bridge, where we help virtual care providers across the industry access in-network coverage. Menopause has been one of our fastest-growing segments, and in this piece, we'll explain why. Patient demand is huge, but demand alone doesn't explain the boom. 

Three forces explain the rapid rise: 

• Hormone replacement therapy no longer carries fear-inducing warning labels.
• Treating menopause is no longer taboo.
• Menopause care is unusually well-suited to virtual care.

Together, they explain why the founders who arrived first and built durable, evidence-based practices are sitting on some of the most valuable patient relationships in women's health. Menopause is what we internally refer to as a digital health “triple threat.”

Reserve Your Spot for Upcoming Webinars!

The clinical reset

The clinical reset is a reversal of a 20-year mistake. The findings published in 2002 by the Women's Health Initiative scared a generation away from hormone replacement therapy (HRT) after falsely linking it to elevated cardiovascular disease, breast cancer, and dementia risks. 

The study was built on existing evidence that HRT benefits women who start near menopause. Its goal was to test whether those benefits extended to women who started later, so the enrolled population skewed older than the typical patient starting HRT. The absolute risk numbers were small, but were reported in relative terms, making them sound enormous. Prescription rates cratered.

As a result, a generation of women lived through hot flashes, brain fog, sleep loss, and bone density decline because their doctors — and they themselves — had been told the alternative was dangerous. Since then, reassessments of the data have told a different story: for most women in early stages of perimenopause or menopause, the benefits of starting HRT substantially outweigh the risks.

The consensus has now caught up, but it’s taken time. Several of the most important shifts in thinking were only recently implemented. In 2024, the American College of Obstetricians and Gynecologists reaffirmed Practice Bulletin No. 141, supporting HRT as the most effective therapy for vasomotor symptoms in symptomatic women under 60 within 10 years of menopause onset. In November 2025, the Food and Drug Administration, the agency that had scared women by placing the Black Box Warning on all estrogen products, announced that it was removing those warnings from six menopausal HRT products.

Change is moving slowly, even with consensus shifting. Only a third of relevant medical residency programs have a menopause curriculum, according to a 2023 survey of U.S. OB/GYN residency program directors published in Menopause. Most practicing OB/GYNs report feeling unprepared to manage symptoms beyond basic counseling. Patients often leave a 12-minute office visit with an SSRI, a "wait it out" recommendation, or no prescription at all. The system is failing them. By the time women turn to a virtual menopause clinic, their patience has run out.  

The cultural shift

The cultural piece runs alongside the clinical one. Once patients experienced female-centered care for fertility and pregnancy, they started demanding the same standard for menopause. Add a layer of advocacy from celebrities like Naomi Watts (Stripes), Halle Berry (Respin), and Michelle Obama, and menopause has shifted from medically taboo to a category patients actively seek out and call for demand. The clinical reset makes the treatment accessible. The cultural shift makes patients more likely to ask for it.

The business model

Menopause is the only category that combines this much pent-up demand with a business model so well aligned with virtual care. 

Start with the demand pool: Women spend 25% more of their lives in poor health compared to men. Roughly 64 million U.S. women are 50 or older, with another 1.3 million entering menopause each year, and McKinsey pegs the preventive care gap for this cohort at $50 billion. 

The supply side is still catching up to a generation of suppressed demand. This gap is what makes customer acquisition work in a way most people miss. Organic awareness is high because the cultural taboo has lifted faster than the supply of providers, and patient communities online and through word of mouth actively recommend providers to each other. Paid channels are still affordable, because menopause has not yet been bid up by competition the way DTC categories like hair loss and GLP-1s have. Some but not all operators in the category report CAC well below those saturated verticals, and conversion is high because patients arrive ready to be treated. The only other segments where we see such good metrics are dieticians and care management/navigation.

Reimbursement is what sets durable operators apart from the rest. A menopause visit can be considered chronic disease management with complex prescribing, which codes as a higher-acuity E/M visit. Reimbursement is around $160-170 for the initial visit and $120-130 for follow-up (2026 CMS national rates). That holds up well against the unit economics of virtual urgent or primary care, and it reflects the downstream value: clinics in this space manage vasomotor symptoms, protect against bone loss and osteoporosis, lower type 2 diabetes risk, and support urogenital health, all areas where costs compound when care is delayed.

The model also doesn't depend on a high-cost specialist. Most menopause care is protocol-driven, based on patient symptoms, and can be delivered by the same specialties that care for women throughout their lifespan (e.g., primary care, internal medicine, OB/GYN). The clinics that best solve insurance contracting and billing have a structural advantage that compounds over time.

The clinical workflow maps to virtual very well, even natively. Early HRT titration requires check-ins every 4 to 8 weeks until symptoms stabilize. That cadence is painful for patients inside a brick-and-mortar practice, but not inside a virtual one. Async messaging, e-prescribing, and structured intake keep cost-to-serve low, even as the frequency of visits per patient increases. We aren’t seeing much reimbursement yet for asynchronous forms of care, including messaging, outside of CCM or CHI - and that wouldn’t apply to most menopause patients. 

Menopause companies have the opportunity to build a moat. That matters, especially at a time when companies like Medvi are selling millions of dollars of prescription medicines purely on the basis of price (aka, no defensibility). Once a clinic has built trust and a working HRT regimen with a patient, it is positioned to support her holistically. Behavioral health, thyroid and adjacent endocrine work, bone health, lab testing, and cardiometabolic care are natural extensions of an established menopause relationship. The longitudinal clinical relationship is the business.

What to watch out for

The category does have operational landmines, and the founders who are moving fast are also the ones most exposed. The good news is that operators who plan ahead and have the right partners can avoid them.

Testosterone therapy is the clearest example. Off-label T-therapy for women is increasingly common in menopause care, but the prescribing rules vary by state, and DEA scheduling adds another layer of complication. Clinics must develop clear, state-level policies to navigate the complex prescribing requirements for T-therapy. Senators Warren and Markey are pushing to deschedule it, mostly to expand access to gender-affirming care. That change would lift a prescribing tax on menopause clinics overnight, and operators who are already prepared for that shift will compound the benefit. 

Marketing claims around "bioidentical" medicines get clinics into trouble. The term has no regulatory definition, and the FDA has made clear that using it to imply safety, superiority, or natural origin for a compounded product is misleading under the Food, Drug & Cosmetics Act. The enforcement template is already visible in the GLP-1 space: in September 2025, the FDA issued more than 50 warning letters to compounders and telehealth platforms for claiming compounded semaglutide was "the same" as Ozempic or Wegovy. In our view, the same logic applies to compounded HRT. Clinics whose marketing leans on "bioidentical" as a differentiator are building on a foundation the FDA is actively working to remove.

Compounded products don't get reimbursed, and that ceiling matters more than most operators realize. Payers cover FDA-approved HRT — estradiol patches and gels, micronized progesterone, oral estradiol — as formulary medications. Compounded preparations are excluded by most commercial plans as unapproved or experimental, which means patients pay out of pocket. Clinics built primarily on cash-pay compounded HRT are operating with a scalability ceiling and a floor that can move. In-network operators prescribing FDA-approved products are building the documented outcomes history that payers reward over time. Clinics that want durable, scalable practices need to be operating on the FDA-approved formulary stack.

Bottom line, the unique regulatory risks in menopause care are real but avoidable for operators who plan ahead and build on the FDA-approved, in-network stack.

Where the category is going

Two open questions will shape the next 18 to 24 months.

The first is the next pharmacological wave, which is a business question as much as a clinical one. Two NK3 receptor antagonists are now FDA-approved for vasomotor (e.g., hot flash) symptoms: Astellas's Veozah (2023) and Bayer's Lynkuet (October 2025), the first dual NK1/NK3 antagonist in the class. Cendifensine is showing strong phase 2 data. ANI Therapeutics' estradiol gel 0.06% was recently approved. Clinics that integrate these molecules quickly widen their addressable pool, especially patients who cannot or will not take HRT, and pull new visit volume from existing patients reconsidering their protocol. Clinics that move slowly will lose share to the ones that move fast.

The second is what we call “the endgame.” Whether menopause clinics graduate into broader women's midlife platforms, or are absorbed into larger primary-care-services-for-women, is an open question. Either path requires the same foundation: trusted relationships and a clinical operating model that scales beyond a single condition. The operators who have already started building toward that platform layer, doing so by layering in FDA-approved products and with in-network economics, are the ones with optionality on the outcome.

Our bet: patients pick a virtual provider to solve a specific problem — menopause, in this case — and expand from there as trust compounds. OB/GYNs will keep owning the in-person work that requires a physical exam, but the longitudinal relationship sits with whoever earned the first visit. A platform built around a specific life stage, rather than one trying to be generalized primary care for women, is the version most likely to win.

Coming up

In a follow-up piece, we’ll sit down with founders building across this category to discuss how unit economics work, where the next wave of growth comes from, and how to build durable patient trust as the category matures.

If you are operating in this space or considering entering it, we want to hear what you are seeing. Reply to this email or message us directly.

Keaton Bedell and Sarah Thomas are Co-Founders of Bridge. Erin Flynn is Bridge's Clinical Quality and Informatics Lead. Bridge is the insurance billing infrastructure for virtual care companies building toward in-network, evidence-based care.

About our Author

Keaton Bedell is a co-founder at Bridge, He writes extensively on healthcare strategy and startup operations, frequently focusing on the challenges healthcare founders face, particularly the difficulty of maintaining focus amidst complex market pressures. His writing covers industry trends, such as the evolution of billing models (e.g., the transition away from the "Per Employee Per Month" or PEPM model) and the shift of virtual care companies toward becoming medical providers.